Taysha Gene Therapies
TSHA
39 hedge funds and large institutions have $9.05M invested in Taysha Gene Therapies in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 10 increasing their positions, 11 reducing their positions, and 7 closing their positions.
9% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 11
4.94% less ownership
Funds ownership: 26.3% → 21.35% (-4.9%)
11% less funds holding
Funds holding: 44 → 39 (-5)
32% less capital invested
Capital invested by funds: $13.3M → $9.05M (-$4.22M)
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
71% less call options, than puts
Call options by funds: $2K | Put options by funds: $7K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
QPW
Quantum Private Wealth
Tampa,
Florida
|
+$105K |
| 2 |
Millennium Management
New York
|
+$99.8K |
| 3 |
Squarepoint
New York
|
+$58.4K |
| 4 |
DAS
Dynamic Advisor Solutions
Phoenix,
Arizona
|
+$32.6K |
| 5 |
Morgan Stanley
New York
|
+$31.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.4M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$341K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$242K |
| 4 |
LCM
Laurion Capital Management
New York
|
-$87.4K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$79.8K |
TSHA Hedge Fund Activity: Q2 2023 in Review
39 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q2 2023, worth a combined $9.05M — down 32% from $13.3M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of TSHA and 2 opened new positions — a net loss of 5 holders — while 11 trimmed existing stakes and 10 added.
The largest buyer was Quantum Private Wealth, adding an estimated $105K. The largest seller was Fidelity Investments, cutting an estimated $1.4M.
- 39 institutional investors held Taysha Gene Therapies (TSHA) as of Q2 2023, down from 44 in Q1 2023.
- Funds reported $9.05M of Taysha Gene Therapies stock for Q2 2023, down 32% quarter-over-quarter.
- 2 funds opened new Taysha Gene Therapies positions in Q2 2023 and 7 closed out, a net change of -5 holders.
- The largest Taysha Gene Therapies buyer in Q2 2023 was Quantum Private Wealth, an estimated $105K added.
- The largest Taysha Gene Therapies seller in Q2 2023 was Fidelity Investments, an estimated $1.4M sold.
Based on aggregated 13F filings for Q2 2023.